Synthon Baga3 Is A Joint Venture Between The Argentine Pharmaceutical Company Grupo Baga3 And The Dutch Firm Synthonthe Company Focuses On Developing Treatments For Neurological And Immune Disorderswith A Strong Emphasis On Multiple Sclerosisms One Of Its Key Offerings Is The Respuestas Ma Ltiples Patient Support Programwhich Aims To Enhance The Quality Of Life For Individuals With Ms By Providing Comprehensive Support And Resourcessynthon Baga3 Specializes In Biological And Biotechnological Products Targeting Multiple Sclerosispositioning Itself To Compete With Established Ms Treatments In The Marketoperating From Buenos Airesargentinasynthon Baga3 Is Part Of A Larger Network Of Pharmaceutical Manufacturing And Research Facilities Linked To Grupo Baga3Which Has A Rich History In The Industrythe Leadership Team Includes General Manager Carlos Pellegrini And Marketing Manager Sergio Guerreroboth From Grupo Baga3
